Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | AR | P10275 | 1/20 | 0.44 |
| ▸ | HTR6 | P50406 | 3/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA4 | P22748 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.42 |
| ▸ | IL1RN | P18510 | 1/20 | 0.41 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28098875 | 1.00 | CA1 (0.47) | CA1CA2ARHTR6CA12 | |
| SCHEMBL3763304 | 0.85 | CA1 (0.54) | CA1CA2ARHTR6CA12 | |
| SCHEMBL12789656 | 0.85 | KEAP1 (0.52) | CA1CA2ARCA12CA4 | |
| Hydrochloric Acid SCHEMBL21633570 | 0.83 | CA1 (0.52) | CA1CA2ARHTR6CA12 | |
| SCHEMBL13771643 | 0.83 | CA1 (0.50) | CA1CA2CA12CA4CA7 | |
| SCHEMBL11210096 | 0.82 | AR (0.58) | ARLMNAHPGD | |
| SCHEMBL14390532 | 0.82 | AR (0.58) | ARLMNAHPGD | |
| SCHEMBL6533144 | 0.80 | CA1 (0.56) | CA1CA2ARCA12CA4 | |
| SCHEMBL29036734 | 0.80 | AR (0.46) | CA1CA2ARCA12CA4 | |
| SCHEMBL251932 | 0.80 | AR (0.60) | ARKEAP1LMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9006426-B2 | Squaric acid derivatives as inhibitors of the nicotinamide | TOPOTARGET A/S (DK) | 2015-04-14 | — | — | US | disclosed |
| US-20140357599-A1 | NOVEL UREA AND THIOUREA DERIVATIVES | ONXEO DK, BRANCH OF ONXEO S.A., FRANCE (DK) | 2014-12-04 | — | — | US | disclosed |
| US-8871747-B2 | Urea and thiourea derivatives | TOPOTARGET A/S (DK) | 2014-10-28 | — | — | US | disclosed |
| US-20120225847-A1 | SQUARIC ACID DERIVATIVES AS INHIBITORS OF THE NICOTINAMIDE | ONXEO DK, BRANCH OF ONXEO S.A., FRANCE (DK) | 2012-09-06 | — | — | US | disclosed |
| US-20120010172-A1 | NOVEL UREA AND THIOUREA DERIVATIVES | MCDERMOTT WILL & EMERY LLP (DC) | 2012-01-12 | — | — | US | disclosed |
| WO-2009086835-A1 | NOVEL CYANOGUANIDINES | TOPOTARGET A/S (DK) | 2009-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010172-A1 | NOVEL UREA AND THIOUREA DERIVATIVES | TST, NAMPT, NNMT | CA1 4533/4885CA2 4675/4885AR 1069/4885 |
| US-20140357599-A1 | NOVEL UREA AND THIOUREA DERIVATIVES | TST, NAMPT, NNMT | CA1 4533/4885CA2 4675/4885AR 1069/4885 |
| US-20120225847-A1 | SQUARIC ACID DERIVATIVES AS INHIBITORS OF THE NICOTINAMIDE | SUCNR1, NAMPT, NAPRT | CA1 1638/4885CA2 2382/4885AR 356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.